NeuroSense Receives Nasdaq Delisting Notices for Minimum Bid Price & Market Value Requirements
NRSN sits 27% above its 52-week low of $0.63.
Summary
NeuroSense Therapeutics received two Nasdaq notifications for failing to meet the minimum bid price and market value requirements, initiating a compliance period to avoid delisting.
Key Events · Corporate Governance and Compliance · NRSN
-
Receipt of Nasdaq Notifications
NeuroSense Therapeutics received two notification letters from Nasdaq on April 2, 2026, indicating non-compliance with continued listing requirements.
-
Non-Compliance with Minimum Bid Price
The company's ordinary shares traded below $1.00 for 30 consecutive business days (February 18 - March 31, 2026), violating Nasdaq Listing Rule 5550(a)(2).
-
Non-Compliance with Market Value of Listed Securities (MVLS)
The company's MVLS was below $35 million for 30 consecutive business days over the same period, violating Nasdaq Listing Rule 5550(b)(2).
-
Compliance Period Established
NeuroSense has 180 calendar days, until September 29, 2026, to regain compliance with both requirements. This requires the stock to close at or above $1.00 and the MVLS to be $35 million or more for a minimum of 10 consecutive business days.
Analysis · NRSN · Life Sciences
NeuroSense Therapeutics has received formal notifications from Nasdaq regarding non-compliance with both the minimum $1.00 bid price and the $35 million market value of listed securities (MVLS) requirements. This is a critical development, following closely on the heels of the company's 'going concern' warning reported in its 20-F filing on March 31, 2026. While these notifications do not have an immediate effect on trading, they signal a significant escalation of financial distress and pose a substantial threat to the company's Nasdaq listing. The company has until September 29, 2026, to regain compliance, which will likely require a reverse stock split or a substantial increase in market valuation, both challenging given the current financial situation. Failure to regain compliance could lead to delisting, severely impacting liquidity and investor confidence.
At the time of this filing, NRSN was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.7M. The 52-week trading range was $0.63 to $2.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.